{"id":"NCT02305446","sponsor":"Novartis","briefTitle":"Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.","officialTitle":"Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2014-12-02","resultsPosted":"2015-11-02","lastUpdate":"2016-01-05"},"enrollment":55,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis, Meningococcal, Serogroup B"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal (group B) multicomponent recombinant adsorbed vaccine","otherNames":["rMenB+OMV NZ"]}],"arms":[{"label":"rMenB+OMV NZ","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the Meningococcal Group B Vaccine in other studies.","primaryOutcome":{"measure":"Number of Subjects Reporting Unsolicited Adverse Events (AEs).","timeFrame":"From day 1 to day 7 after each vaccination (Vaccination 1: Day 1 to Day 7; Vaccination 2: Day 61 to Day 67)","effectByArm":[{"arm":"rMenB+OMV NZ","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Poland"]},"refs":{"pmids":["28580917"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":55},"commonTop":[]}}